Invitrogen Licenses Harvard's Click Chemistry Technology for Cell-Based Assays
Invitrogen has licensed cell proliferation assay technology from Harvard University that it will use in its click chemistry technology-related programs, the company said this week.
Invitrogen said it is adding the Harvard technology to its click chemistry IP portfolio, which also includes a license from the Scripps Research Institute, and agreements with the University of California, Berkeley, the California Institute of Technology, and the National Institutes of Health.
Those agreements are for marketing Click-iT kits for glycoprotein profiling that allow researchers to label glycoprotein subsets in live cells and in extracts or purified samples.
The license for Harvard’s IP will allow Invitrogen’s researchers “to examine cell proliferation in parallel with other biomarkers,” Augie Sick, Invitrogen VP and GM of Cellular Analysis, said in a statement.
This ability will enhance the “power of this fundamental method for assessing cell health, determining genotoxicity and evaluating anti-cancer drugs,” Sick said.
The company also said it is developing new click chemistry applications, such as protein synthesis detection. Invitrogen said the click technology is suitable for flow cytometry, fluorescence microscopy, and high-content screening.
Financial terms of the agreement were not released.
Edgeline Holdings Takes Option to Cancer Rx Tech from UT’s MD Anderson
Edgeline Holdings, a Houston-based intellectual property holding company, said last week that it has signed an option agreement with the University of Texas MD Anderson Cancer Center for cancer treatment technologies.
Under the terms of the agreement, Edgeline has the exclusive right to negotiate a license to five technologies relating to the treatment of various cancers over a nine-month period.
During this period, Edgeline has the right to evaluate the patents’ rights, potential products and markets, and to negotiate a license for use of the patents.
“This agreement gives us the necessary time to allow our subsidiary, Intertech Bio, to properly evaluate the potential of these technologies,” Leonard Ivins, CEO of Edgeline, said in a statement.
Edgeline is a publicly traded holding company that specializes in discovering and acquiring niche technologies to incubate into market-ready products, the company said.
GeoPharma Acquires Ovarian Cancer Dx Test from USF
GeoPharma said last week that it has signed an agreement with the University of South Florida Research Foundation to acquire worldwide patent rights for a diagnostic technology for detecting early-stage ovarian cancer from patient urine samples.
GeoPharma, based in Largo, Fla., will initiate necessary steps for approval from the US Food and Drug Administration. Preliminary clinical studies have been conducted at USF, and further studies are in progress, GeoPharma said.
Financial terms of the agreement were not disclosed.
Intuitive Surgical, CalTech Settle Lawsuit
Intuitive Surgical, a robotic surgical tools manufacturer, said this week that the California Institute of Technology will dismiss its lawsuit against the company as part of a licensing deal, according to a filing with the US Securities and Exchange Commission.
Intuitive also said that it has agreed with Cal Tech to enter into a non-exclusive license under the school’s patent portfolio.
The terms of the license arrangement have not been disclosed, and are considered immaterial to the Company’s financial statements, Intuitive said.
In January, the company said the university filed a lawsuit, claiming patent infringement.
Weizmann Tech-Transfer Arm Yeda Wins $120M in ImClone, Sanofi-Aventis Settlement
ImClone Systems said last week that it has signed a settlement agreement with Yeda Research and Development Company, the tech-transfer arm of Israel’s Weizmann Institute of Science, and with Sanofi-Aventis, to end worldwide litigation related to US Patent No. 6,217,866 and its foreign counterparts.
The US patent, entitled “Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same,” is related to ImClone’s colorectal cancer treatment Erbitux.
Under the terms of the settlement, the companies agree that Yeds is the sole owner of the ‘866 patent in the US, and Yeda and Sanofi-Aventis are co-owners of the ‘866 patent’s foreign counterparts.
Pursuant to the terms of the agreement, ImClone and Sanofi-Aventis will each pay Yeda $60 million in cash for full and final settlement of the claims and counterclaims in the matter.
ImClone said that it shall be granted a worldwide license to technology patented under the ‘866 patent. ImClone will also make a contingent payment to Yeda of a “low single-digit royalty” on sales in and outside the US, and will pay Sanofi-Aventis a “low single-digit royalty” on sales outside the US.
ImClone’s worldwide royalty rate for Erbitux sales pursuant to the settlement agreement remains unchanged, the company said.
All terms of the settlement have been finalized and the parties will submit stipulations to the appropriate courts and patent offices in the various jurisdictions, ImClone said.
NCI Offers Prostate Cancer Genotyping Predictive IP
The National Institutes of Health is making a prostate cancer-related genotyping technology available for either exclusive or non-exclusive licensing.
The National Cancer Institute’s Medical Oncology Branch is seeking interested research collaborators to develop, evaluate, or commercialize the use of this technology, which is used to predict survival prognoses for prostate cancer patients.
The NCI’s genotyping technology identifies two polymorphic genetic markers in the SLCO 1B3 gene that can be measured in DNA from a blood sample.
The inventors have provided a correlation between clinical outcome of SLCO 1B3 genotype with median survival of androgen-independent prostate cancer. They also have shown that the genotype can help predict testosterone uptake, which can be helpful knowledge in making clinical decisions.
Additional information about the technology is available here.
Stanford Spinout Fundamental Applied Biology Completes $21M Series B Financing
Fundamental Applied Biology last week said it has completed a $21 million Series B financing to further develop its cell-free protein synthesis technology to produce biologic drugs and vaccines for unmet medical needs.
Prior investor SV Life Sciences led the round, which also included contributions from co-lead investor Alta Partners.
FAB’s cell-free protein synthesis technology was developed by James Swartz, a professor of engineering, bioengineering, and chemical engineering at Stanford University.